Registration and Activity Links - PSYCHIATRY
Distinguished Lectures:
Bipolar Distinguished Lectures
ADHD Distinguished Lectures
Monographs:
New Strategies for Treating ADHD and Associated Comorbidities in Children, Adolescents, and Adults
A Continuing Medical Education Monograph
Released February 15, 2006
New Treatment Approaches in the Management
of Patients with Mood and Anxiety Disorders
A Continuing Medical Education Monograph
Released April 1, 2003
The Role of Atypical Antipsychotics in the Management
of Selected Mental Disorders in Children and Adolescents
A Continuing Medical Education Monograph
Released August 29, 2003
New Treatment Approaches in the Management
of Patients with Mood and Anxiety Disorders
A Continuing Education Monograph
Released April 1, 2003
Faculty
Program Description
Learning Objectives
Credit
Order
Faculty
Martin B. Keller, MD
Mary E. Zucker Professor and Chairman
Department of Psychiatry and Human Behavior
Brown Medical School
Providence, Rhode Island
David V. Sheehan, MD, MBA
Professor of Psychiatry
University of South Florida College of Medicine
Tampa, Florida
Program Description
This continuing medical education (CME) program comprises a monograph and a physician self-assessment test. This activity is designed to provide psychiatrists, primary care physicians, and other health care professionals with an up-to-date overview of published and unpublished clinical data on a relatively new class of psychotropic agents, the atypical antipsychotics. By comparing the efficacy and safety of atypical antiphsychotics with those of conventional treatments, particularly the typical antipsychotics, this monograph presents the clinical rationale behind the growing role these agents are playing in managing patients who have mood and anxiety disorders.
Learning Objectives
After completing this monograph, the reader should be able to:
• Appreciate the ramifications of specific mood and anxiety disorders in terms of their epidemiology and cost of treatment
• Discuss conventional treatment approaches to two key mood disorders, bipolar disorder and treatment-resistant depression, and two key anxiety disorders, obsessive-compulsive disorder (OCD) and posttraumatic stress disorder (PTSD), as well as the diagnostic areas in which the newer, atypical antipsychotics could offer treatment benefits.
• Describe recent clinical data comparing the atypical antipsychotics—particularly risperidone, olanzapine, quetiapine, and ziprasidone—and their roles in the management of mood and anxiety disorders
• Characterize the safety and tolerability profiles of the new atypical antipsychotics
Credit Designations
This activity is designed for psychiatrists, primary care physicians, and other health care professionals who have an interest in treating patients who have mood and anxiety disorders.
The Network for Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
NCME designates this educational activity for a maximum of 2 category 1 credits toward the AMA Physician’s Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the activity. This designation is valid through April 1, 2006.
The American Academy of Physician Assistants accepts AMA category 1 credit for the Physician’s Recognition Award from organizations accredited by the ACCME.
This activity is supported by an educational grant from Janssen Pharmaceutica Products, L.P.
The Role of Atypical Antipsychotics in the Management
of Selected Mental Disorders in Children and Adolescents
A Continuing Medical Education Monograph
Released August 29, 2003
Faculty
Program Description
Learning Objectives
Credit
Order
Faculty
Robert L. Findling, MD
Associate Professor of Psychiatry and Pediatrics
Case Western Reserve University School of Medicine
Director of Child and Adolescent Psychiatry
University Hospitals of Cleveland
Cleveland, Ohio
Program Description
This continuing medical education (CME) program comprises a monograph and a CME self-assessment test. This activity is designed to provide physicians and other health care professionals with an up-to-date overview of published and unpublished clinical data on the use of atypical antipsychotic agents in children and adolescents with selected neuropsychiatric disorders. By presenting an overview of clinical experience pertaining to the efficacy and safety of atypical antipsychotics, this monograph provides the clinical rationale behind the growing role these agents are playing in the management of children and adolescents with selected neuropsychiatric disorders.
Learning Objectives
After completing this program, the reader should be able to:
• Describe the prevalence and characteristics of selected psychiatric disorders in children and adolescents, including schizophrenia, disruptive behavior disorders, bipolar disorder, autism, and tic disorders
• Identify established treatment approaches to these disorders in children and adolescents, and the areas in which atypical antipsychotics may offer treatment benefits
• Discuss recent clinical data on atypical antipsychotics (specifically risperidone, olanzapine, quetiapine, and ziprasidone) in the management of these disorders in children and adolescents
• Define the safety and tolerability profiles of atypical antipsychotics in children and adolescents with psychiatric disorders
Credit Designations
This activity is designed for child and adolescent psychiatrists, pediatricians, primary care physicians, and other health care professionals who have an interest in treating children and adolescents with psychiatric disorders.
The Network for Continuing Medical Education (NCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
NCME designates this educational activity for a maximum of 2 category 1 credits toward the American Medical Association (AMA) Physician’s Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the activity. This designation is valid through August 29, 2006.
The American Academy of Physician Assistants accepts AMA category 1 credit for the Physician’s Recognition Award from organizations accredited by the ACCME.
This activity is supported by an educational grant from Janssen Pharmaceutica
Products, L.P.